Pfizer Corporation

Xinzhen Yang

Xiaoyuan Sherry Chi

Philip R Dormitzer

Thomas Richard Jones

Ye Che

Seungil Han

Xiayang Qiu

Matthew Curtis Griffor

Xiaojie Yao

Yuhang Liu

Jennifer Anne Nicki

Kyle Paul Heim

The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

Human cytomegalovirus gB polypeptide

The present invention relates to a polypeptide that includes at least one mutation in the fusion loop 1 region and/or in the fusion loop 2 region and/or in the furin-like cleavage site of a human cytomegalovirus gB polypeptide. In one embodiment, the polypeptide undergoes a structural conformation change in response to pH change.

Growing community of inventors

Woodcliff Lake, NJ, United States of America

Xinzhen Yang